IP and Biopharma:
Separating Myth from Reality Series
When we think about prescription medicines, we often see just the final product – a small pill, a vial of liquid, or an autoinjector. What remains invisible is the complex journey of problem-solving, setbacks, and innovations that transformed a promising molecule, itself a needle in a haystack, into an effective treatment. This journey happens thanks to investment secured by patents – and not just the patent on the original active ingredient, but also on each invention that solved a problem along the way.
In recent years, pharmaceutical patents have become a flashpoint in healthcare policy debates. Critics claim – often with misleading data – that drug companies misuse the patent system to block generic manufacturers and maintain high prices. They paint a picture of strategic manipulation rather than a process of genuine innovation, suggesting that limiting patents would quickly lower drug prices without consequences.
But what if this narrative fundamentally misunderstands how medicine development actually works?
This series examines critical questions about how patents help to advance biopharmaceutical innovation. We contrast popular misconceptions with evidence-based reality, drawing on patent data, market research, and innovation studies. We demonstrate that multiple patents on a single drug product typically reflect genuine problem-solving that benefits patients and healthcare systems rather than alleged anti-competitive behavior.
While drug affordability is a legitimate concern, addressing it through policies that undermine innovation incentives would jeopardize the development of future treatments. At stake is not just how we regulate existing medicines, but whether we will continue to see the stream of medical breakthroughs that have transformed patient care. By separating myth from reality in pharmaceutical patent debates, we can pursue policies that balance innovation and access without sacrificing either.
Series 1:
Pharmaceutical "Patent Thickets"
Pharmaceutical patents have become a focal point of debate, often portrayed as tools used by companies to stifle competition and maintain high prices. However, the reality is more complex: most drug patents protect genuine scientific solutions that make medicines safer, more effective, and more accessible for patients. This paper challenges the “patent thicket” narrative by presenting evidence that multiple patents on a single drug reflect cumulative innovation rather than anti-competitive behavior—and that generic competition continues to arrive predictably within 13–14 years of approval.
Biopharma IP Myths: Frequently Asked Questions
As with a car, phone, or even a golf club, a medicine represents a series of inventions, each of which may be patented, including improvements that may be added over time. Creating a medicine does not happen in a single Eureka! moment, but over a long process as scientists solve problems.
What people experience as a “medicine” or drug “product” is likely a bundle of inventions.
Each patent represents a particular invention that solves a specific scientific problem encountered during drug development – from improving absorption to enhancing stability –not strategic extensions of monopoly power. These innovations are needed to address the problems that otherwise cause 90% of drug candidates to fail.
Patents protect solutions, not medicines themselves.
Despite critics’ claims, the effective market exclusivity period has remained stable at 13-14 years for decades, regardless of patent count. Generic manufacturers routinely navigate patent landscapes, introducing competition on a predictable timeline.
Multiple patents don’t delay generic competition.
Most of the drugs (61%) currently approved for marketing no longer have any patents, a fact that reminds us that all patents expire and all generic drugs start life as patented drugs. Of those drugs with patents still in force, most have fewer than four. Leading companies in other sectors obtain ten times more patents per R&D dollar than pharmaceutical companies.
Pharmaceutical patenting is moderate compared to other industries.
Restricting the number of patents that can be obtained or enforced would hinder important advancements that minimize side effects and broaden treatment options, without fostering increased generic competition.
Patent caps would harm innovation without helping competition.
Generics now fill 90% of all U.S. prescriptions (up from 13% in 1984), demonstrating that the current patent system successfully balances innovation incentives with competition and patient access.
The generic industry is thriving.
60% of medicines in the market have no patent,
and biopharma patenting is less intensive
than in other sectors.
Download the full report:
Series 2:
"Evergreening"
Critics argue that brand-name drug companies “evergreen” their patents, strategically manipulating the patent system to inappropriately extend market exclusivity, delay generic entry and maintain high prices. In reality, patents cannot be extended indefinitely. They last 20 years from filing, with narrow and specific adjustments to this term only for government-caused delays. Moreover, later patents on drug improvements don’t extend earlier patents or block the generic entry of drug products using the inventions that were embodied in the original version of the drug. The “evergreening” metaphor obscures these legal realities and misdirects policy discussions. This series of papers tackles common myths about patents and market exclusivity for innovative medicines.
Biopharma IP Myths: Frequently Asked Questions
Beyond the patent on the original molecule, there are essentially two types of patents that cover further innovations on a pharmaceutical product: patents on innovations that occur before regulatory approval (to develop the original molecule into a safe and effective drug that can receive regulatory approval), and patents on innovations that occur after approval (to improve efficacy, user experience, patient benefits, or extend benefits to more patients).
What people experience as a “medicine” or drug “product” is likely a bundle of inventions.
Later-filed patents on improvements to existing medicines protect distinct inventions that make medicines safer, more effective, or easier to use. They can be crucial to making a compound into a workable drug, or to improving an existing medicine. These patents do not extend the original patent, and they do not block copying of the original product once its patents expire. Studies consistently find that later patents don’t delay generic entry.
Patents protect solutions, not medicines themselves.
Critics who treat every patent related to a drug as preventing entry of any generic version misinterpret how generics work. Generics copy specific approved drug products, and the effect of patents on generic entry depends only on the patents covering that specific product. Treating the initial compound patent as the only legitimate patent is like saying only the engine patent matters for a car.
Multiple patents don’t delay generic competition.
When tested against real data, “evergreening” claims consistently fail; one study found that predictions are wrong by an average of 7 years. Despite predictions of extended monopolies, U.S. market exclusivity periods have remained stable at about 13-14 years since the 1980s.
Pharmaceutical patenting is moderate compared to other industries.
Generics enter the market quickly once patents expire, benefitting from legal advantages such as abbreviated approval pathways, incentives to challenge patents, automatic substitution laws, and a patent infringement safe harbor for activities associated with regulatory approval. Today, generics now fill over 90% of U.S. prescriptions.
Patent caps would harm innovation without helping competition.
Patents expire 20 years from the filing date, save for Patent Term Adjustments (PTA) and Patent Term Extensions (PTE). These adjustments compensate for delays in patent examination and regulatory review, and they are the product of specific mathematical formulas with caps. They cannot extend patents indefinitely or repeatedly.
The generic industry is thriving.
Download the full report:
Series 3:
"Taxpayer pays twice"
We often see only the final form of prescription medicines—a pill, vial, or autoinjector—without noticing the invisible journey of problem-solving, setbacks, and innovation that turns a promising molecule into a treatment. This process is fueled by patent-backed investment, not just in the original ingredient, but in every solution developed along the way.
© 2025 UnpackingIP
Sponsored by Interpat